Vaccitech’s VTP-200 Ph Ib/II Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-Related Cervical Lesions

By
Jamie Kang
-
0
204
Vaccitech plc announced topline interim data from the HPV001 study, a Phase Ib/II clinical trial of VTP-200 in women with low-grade cervical HPV lesions.
[Vaccitech plc]
Press Release